The MIRRA Trial: Mepolizumab vs. placebo for EGPA


EGPA PATIENTS (136 PTS)

MEPOLIZUMAB (68 PTS)

PLACEBO CONTROL (68 PTS)

PATIENTS WHO ACHIEVED REMISSION DURING THE TRIAL:

REMISSION 53%
NO REMISSION 47%

PATIENTS WHO WERE IN REMISSION AT THE END OF THE TRIAL (WEEK 48):

REMISSION 32%
RELAPSE 21%
NO REMISSION 47%
REMISSION 3%
RELAPSE 16%
NO REMISSION 81%